Scientists developed a light-responsive artificial nucleic acid that enables reversible, controllable crosslinking within DNA, opening doors for nanomedicine, DNA nanotechnologies and drug delivery.

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT ...

This article was originally published in Just Security.

SALT LAKE CITY, Nov. 7, 2025 /PRNewswire/ -- Resonant, a Renew Biotechnologies subsidiary developing novel diagnostic tools for neurodegenerative diseases, announces the receipt of "DNA Sequencing ...

CORONA, Calif., Nov. 10, 2025 /PRNewswire/ -- The DNA Company, a global leader in functional genomics and personalized health, has been named Functional Genomics Innovation of the Year in the 2025 ...

STONY BROOK, NY / ACCESSWIRE / July 13, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has acquired ...